We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


AiCuris Receives Orphan Drug Designation for Letermovir (AIC246) from FDA

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AiCuris Receives Orphan Drug Designation for Letermovir (AIC246) from FDA"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

This decision was made on 12 December 2011 by the FDA Office of Orphan Products Development.

Letermovir has recently successfully completed a phase IIb trial for the prophylaxis of HCMV infection and disease in bone marrow transplanted patients. Results will be announced shortly.

“After orphan drug designation was granted earlier last year in Europe, we are very pleased to have now also received this designation in the USA. For the further development of this innovative drug, the Orphan Drug Designation will provide easier access to scientific support by the agencies, which will help to develop new treatment paradigms against this dangerous virus” commented AiCuris CEO, Prof. Rübsamen-Schaeff.